<DOC>
	<DOCNO>NCT00534261</DOCNO>
	<brief_summary>This study find patient Relapsing Remitting Multiple Sclerosis treat Interferon beta-1a improve quality life treatment Interferon beta-1a</brief_summary>
	<brief_title>Does Quality Life Improve Multiple Sclerosis Patients Treated With Interferon Beta-1a ?</brief_title>
	<detailed_description>The study open-label , multi-center , international post-marketing study ( phase 4 ) . Eligible patient interferon naïve patient suffer relapse MS . The duration subject 's participation study maximum 26 month .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Relapsing Remitting Multiple Sclerosis Interferon naïve Eligible interferon beta1a ( AVONEX® ) therapy per Summary Product Characteristics : Subject relapse MS &gt; 1 year Subject experience 2 exacerbation last 2 year Subject EDSS [ 5 ] score &lt; 5.5 Subject ambulant Diagnosis MS define progressive History significant cardiac , hepatic , pulmonary , renal disease ; immune deficiency ; medical condition would preclude therapy interferon beta History severe allergic anaphylactic reaction history hypersensitivity human albumin History seizure within 3 month prior start study History intolerance acetaminophen ( paracetamol ) , ibuprofen , naproxen NSAIDs , would preclude use least one study History intolerance interferon Previous use interferon beta Female subject pregnant breastfeeding For female subject , unless postmenopausal surgically sterile , unwillingness practice effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Avonex</keyword>
	<keyword>Interferon beta-1a</keyword>
</DOC>